Acceleron Pharma Inc Watch

from 8-K 27 pages Acceleron Pharma Inc. 4,864,864 Shares1 Common Stock ($0.001 Par Value) Underwriting Agreement

from 8-K 5 pages Acceleron Presents Topline Results of the Pulsar Phase 2 Trial of Sotatercept in Patients With Pulmonary Arterial Hypertension - Data Presented During ‘Breaking News’ Session of the American Thoracic Society 2020 Virtual Conference (Ats 2020 Virtual) Show the Pulsar Trial Achieved Its Primary Endpoint: A Statistically Significant Mean Reduction in Pulmonary Vascular Resistance (Pvr) - - Patients on Stable Background Therapy Who Were Treated With 0.3 Mg/Kg or 0.7 Mg/Kg of Sotatercept Experienced Mean Pvr Reductions of Approximately 21% and 34%, Respectively - - The Trial Also Achieved a Statistically Significant All-Dose Mean Improvement From Baseline of 54 Meters in the Key Secondary Endpoint of Six-Minute Walk Distance (6mwd) and a Placebo Corrected Improvement of 25 Meters (All Doses Combined) - - Sotatercept Was Generally Well Tolerated; Adverse Events Were Consistent With Previously Published Data on Sotatercept in Clinical Trials in Other Patient Populations - - Company-Hosted Investor and Analyst Conference Call and Webcast With Guest Pah Key Opinion Leaders to Be Held Today, Wednesday, June 24th at 4:30 P.M. Edt

from 8-K 34 pages Acceleron Pharma Inc. 5,348,838 Shares(1) Common Stock ($0.001 Par Value) Underwriting Agreement

from 8-K 34 pages Acceleron Pharma Inc. 5,405,406 Shares(1) Common Stock ($0.001 Par Value) Underwriting Agreement

from 8-K 34 pages 3,750,000 Shares Acceleron Pharma Inc. Common Stock ($0.001 Par Value) Underwriting Agreement January 5, 2016

from SC 13D/A 1 page Joint Filing Agreement Pursuant to Rule 13d-1

from S-1/A 30 pages Acceleron Pharma Inc. [·] Shares (1) Common Stock ($0.001 Par Value) Underwriting Agreement

from S-1/A 34 pages Acceleron Pharma Inc. [ ] Shares (1) Common Stock ($0.001 Par Value) Underwriting Agreement